RYTM Stock: Price, Earnings History and SEC Filings
Rhythm Pharmaceuticals, Inc. (RYTM) last traded at $92.57, down 0.54% on the latest session and down 2.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.73 against an analyst estimate of $-0.81, a beat of 9.9%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
RYTM earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $-0.73 | $-0.81 | +9.88% |
| Mar 2026 | May 5, 2026 | $-0.83 | $-0.86 | +3.49% |
| Dec 2025 | Feb 26, 2026 | $-0.73 | $-0.79 | +7.59% |
| Sep 2025 | Nov 4, 2025 | $-0.82 | $-0.72 | -13.89% |
RYTM beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How RYTM reacts to earnings
Across its last 8 earnings releases, RYTM moved 4.1% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-04 | Before open | +2.92% |
| 2026-05-05 | Before open | +7.86% |
| 2026-02-26 | Before open | -1.09% |
| 2026-01-09 | Before open | +3.65% |
| 2025-11-04 | Before open | -7.69% |
| 2025-08-05 | Before open | -1.85% |
| 2025-05-07 | Before open | +3.06% |
| 2025-02-26 | Before open | +4.49% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
RYTM financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $190M | -$197M | -$117M | -103.6% | $-3.11 |
| 2024 | $130M | -$261M | -$114M | -200.3% | $-4.34 |
| 2023 | $77M | -$185M | -$136M | -238.5% | $-3.20 |
| 2022 | $24M | -$181M | -$174M | -766.2% | $-3.47 |
| 2021 | $3M | -$70M | -$146M | -2207.1% | $-1.40 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for RYTM
- 10-Q · Aug 4, 2026
- 8-K · Aug 4, 2026Results of operations, Regulation FD disclosure, Other events
- 8-K · Jun 25, 2026Shareholder vote
- 8-K · Jun 15, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 10-Q · May 5, 2026
- 8-K · May 5, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 29, 2026
- 8-K · Apr 3, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Mar 26, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Mar 20, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
Insider filing activity
RYTM insiders filed 7 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
RYTM news
- CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseOct 29, 2026 · finance.yahoo.com
- Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOct 27, 2026 · finance.yahoo.com
- William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates CoverageOct 21, 2026 · finance.yahoo.com
- Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026Oct 21, 2026 · finance.yahoo.com
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. (RYTM) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.